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Evaluation of a new turbidimetric assay for  von
Willebrand factor activity useful in the general
screening  of von Willebrand disease 
We evaluated a new assay (HemosIL™VWF
Activity on ACL-Futura) in the screening of VWD.
Samples from healthy donors and previously diag-
nosed VWD patients were blindly analyzed by this
new activity assay and standard VWF:RCo. Results
agreed and both assays showed a similar sensitivi-
ty for the screening of VWD. 
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Von Willebrand disease (VWD), the most frequent
inherited bleeding disorder, is caused by a deficiency
and/or abnormality of the von Willebrand factor
(VWF).1,2 The revised classification of VWD identifies
two major categories, characterized by quantitative
(types 1 and 3) or qualitative (type 2) VWF defects.2 The
most common test of VWF activity, the assay of
VWF:RCo together with VWF:Ag is traditionally consid-
ered the first step in the diagnosis of VWD, with the
VWF:RCo/Ag ratio being recommended to discriminate
type 1 from type 2A, 2B and 2M VWD.1,2 Given the
complexities of the aggregometric test, several alterna-
tive laboratory methods have been proposed to measure
VWF activity. Monoclonal antibody-based ELISA,3,4
Elisa-based VWF:RCo,5,6 rapid assays for VWF:RCo using
coagulometers,7 and assays measuring the binding of
VWF to collagen.8 The aim of this study was to evaluate
the novel fully automated HemosIL™VWF Activity
assay on the ACL-Futura automated coagulometer
(Instrumentation Laboratory) as a potential screening
test for the diagnosis of VWD.9,10 The assay uses latex
sensitized with monoclonal antibodies (RFF VIII:R/1)3
directed against the platelet binding site of VWF (GPIb
receptor). The activity of VWF is determined by meas-
uring the increase of turbidity produced by the aggluti-
nation of the latex particles as a consequence of the
interaction between the GPIb receptor of VWF and the
monoclonal antibodies. The lower limit of linearity has
been reported at 12.5IU/dL.9 A set of 57 normal controls
and 70 VWD patients from two Hemophilia Centers
were blindly analyzed in the R&D laboratory of Biokit
with HemosIL™VWF:Ag, HemosIL™VWF Activity and
VWF:RCo (Dade Behring) performed on an optical
aggregometer. All  methods were used to analyze sam-
ples which were then classified as normal or VWD type
1, 2, or 3 using the same criteria in both activity assays.
The cut-off declared by the HemosIL based on ABO
group was used to define normality or VWD, and the
Activity/Antigen (Act/Ag) ratio was used to define
quantitative (type 1) or qualitative (type 2) VWD using
0.7 as cut-off.1 Sample values below detectability were
classified as type 3. 
After classification and database lock, blindness was
disclosed by the two Hemophilia Centers where the
patient samples were classified according to the clinical
and laboratory findings. Table 1 shows the mean VWF
concentration in IU/dL±SD (standard deviation)
obtained for each assay. The first column shows the
Classification according to the Haemophilia Centers.
Nine samples from the Vicenza group which correspond
to type 1 according to the last classification scheme,2 are
shown separately. The last columns show the mean
Act/Ag ratios. The mean VWF:Ag value for the VWD
type 3 samples was below detectability, hence this
group is not shown in this Table. Comparing the mean
values of the two activity assays, only the type 2A sam-
ples show a highly significant difference (p=0.0006).
Comparing the mean values of the Act/Ag ratios for
both activity assays, the HemosIL shows a higher
Act/Ag ratio than the VWF:RCo for type 2A samples
(p=0.002), while the other subtypes of VWD show no
difference. 
The comparison of HemosIL™ VWF Activity to the
reference method VWF:RCo shows a Passing & Bablok
fitted curve y=0.95x+1 and Pearson correlation of
r=0.956 (p<0.0001). The ability of the activity assays as
screening tests to distinguish between VWD patients
from non VWD was evaluated. One out of 70 VWD
samples which corresponded to a type1 VWD patient,
was classified as Normal by both activity assays. Thus
the sensitivity for the VWD was 98.6% for both. From
the remaining 69 VWD samples which resulted in a
VWD type from both activity assays, we compared their
ability to discriminate between quantitative and qualita-
tive deficiencies. Table 2 shows the classification
according to the HemosIL and the VWF:RCo assays for
each group of samples. Sensitivity for qualitative VWD
was 94.7% (95%CI: 86.2%-99.9%) for the HemosIL
and 100% (95%CI:90.7%-100.0%) for the VWF:RCo.
Sensitivity for quantitative VWD was 71.0%
(95%CI:52.0%-85.5%) and 64.5% (95%CI:45.4%-
80.8%) for the HemosIL and the VWF:RCo respectively.
The overall agreement was 84.1% for both assays. 
In conclusion, unlike other indirect tests based on
monoclonal antibodies against epitopes of VWF A1
domain,3,4 the HemosIL™VWF activity correlates with
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Table 1. Descriptive statistics of samples analyzed with HemosIL™ VWF Antigen, HemosIL™ VWF Activity and VWF:RCo.
Classification of VWD VWF:Ag VWF Activity Ratio Act/Ag
according to the 
Hemophilia Centers N HemosIL HemosIL VWF:RCo p HemosIL VWF:RCo p
Normal 57 103.3±38 94.5±41 100.5±47 0.05 0.90±0.1 0.96±0.21 0.01
Type 1 13 30.9±24 29.9±26 23.9±19 0.03 0.82±0.4 0.76±0.3 ns
Type 1Vicenza 9 15.8±12 10.9±8 8.3±4 ns 0.67±0.3 0.61±0.3 ns
Type 2A 14 37.0±18 15.4±9 8.8±5 0.0006 0.44±0.2 0.27±0.2 0.002
Type 2B 12 38.5±14 13.9±8 13.8±7 ns 0.35±0.1 0.36±0.1 ns
Type 2M 12 19.9±15 7.7±4 5.2±2 0.05 0.43±0.3 0.32±0.2 ns
Data are expressed as mean IU/dL±SD. The mean values of the activity assays and the Act/Ag ratios are compared for each sample group. ns: not significant. 
the standard VWF:RCo in all type 1 and 2 VWD vari-
ants. Compared with the classical aggregometric assay
for VWF:RCo, the new assay has the advantage of being
much faster and fully automated, although it has a sen-
sitivity limit of 12.5 IU/dL. HemosIL™ VWF activity, in
combination with the HemosIL™ VWF:Ag appears to
be a useful screening tool in the diagnostic evaluation of
patients with a bleeding diathesis,9,10 although addition-
al VWF tests should always be performed to confirm
and further characterize diagnosis.
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Table 2. Sample classification according to HemosIL™ VWF Activity and VWF:RCo.
Classification according to the Classification in the R&D lab for the Classification in the R&D lab for the 
Hemophilia Centers HemosIL VWF activity VWF:RCo
Clinical VWF # VWD type VWD type
status deficiency samples Norrmal 1 3 2 Normal 1 3 2
Normal 57 54 0 0 3 53 1 0 3
Type 1 quantitative 13 1 8 0 4 1 8 0 4
Type 1 Vicenza quantitative 9 0 4 1 4 0 2 1 6
Type 3 quantitative 10 0 0 9 1 0 0 9 1
Total quantitative 32 1 12 10 9 1 10 10 11
Type 2A qualitative 14 0 1 0 13 0 0 0 14
Type 2B qualitative 12 0 0 0 12 0 0 0 12
Type 2M qualitative 12 0 1 0 11 0 0 0 12
Total qualitative 38 0 2 0 36 0 0 0 38
Classification according to the Hemophilia Centers and the R&D lab for the HemosIL VWF Activity and VWF:RCo. In bold, samples correctly classified. 
